Form 4: Director Michael F. Roman Receives Abbott Stock Grant

Abbott Laboratories Director Michael F. Roman was granted 2,286 restricted stock units under the 2026 Incentive Stock Program.

Summary

• Director Michael F. Roman acquired 2,286 restricted stock units (RSUs) of Abbott Laboratories (ABT) common stock.
• The grant was issued under the Abbott Laboratories 2026 Incentive Stock Program.
• The RSUs are payable on a one-to-one basis in common shares upon the director's separation from service, death, or a change in control.
• Following this transaction, the reporting person's total beneficial ownership is 10,764 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• None identified; this is a standard director compensation disclosure.

Risks

• None identified; this is a routine equity grant disclosure.

Future Outlook

The RSUs will vest and be paid out upon the director's separation from service, death, or a change in control of the company.

Management Comments

• The award is granted under the Abbott Laboratories 2026 Incentive Stock Program.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard corporate governance practices designed to ensure director alignment with long-term company performance in the healthcare and medical device sector.

Comparison to Industry Standards

• The use of restricted stock units for director compensation is consistent with standard practices among S&P 500 companies.
• The payout structure tied to separation from service is a common retention and alignment mechanism for board members.

Corporate Governance

Stakeholder Impact

• Minimal impact on shareholders as this is a standard director compensation event.

Next Steps

• The director will hold these units until separation from service, death, or a change in control.

Key Dates

Keywords

Abbott Laboratories, ABT, Form 4, Director Compensation, Insider Transaction, Restricted Stock Units